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Abstract 
Background and Purpose: Hyperglycemia is a negative prognostic factor following 
acute ischemic stroke but is not known whether glucose is associated with the effects of 
endovascular thrombectomy in patients with large vessel stroke. In a pooled-data meta-
analysis, we analyzed whether serum glucose is a treatment modifier of the efficacy of 
endovascular thrombectomy in acute stroke. 
Methods: Seven randomized trials compared endovascular thrombectomy with 
standard care between 2010 and 2017 (HERMES Collaboration). 1764 patients with 
large vessel stroke were allocated to endovascular thrombectomy (n=871) or standard 
care (n=893). Measurements included blood glucose on admission and functional 
outcome [modified Rankin Scale (mRS) range: 0-6; lower scores indicating less 
disability] at 3 months. The primary analysis evaluated whether glucose modified the 
effect of EVT over standard care on functional outcome, using ordinal logistic 
regression to test the interaction between treatment and glucose level. 
Results: Median (IQR) serum glucose on admission was 120 (104-140) mg/dl 
[6.6mmol/l (5.7-7.7) mmol/l]. Endovascular thrombectomy (EVT) was better than 
standard care in the overall pooled-data analysis [common odds ratio (acOR), 2.00 (95% 
CI 1.69–2.38); however, lower glucose levels were associated with greater effects of 
EVT over standard care. The interaction was nonlinear such that significant interactions 
were found in subgroups of patients split at glucose < or > 90mg/dl (5.0mmol/l) 
[(p=0.019 for interaction, acOR 3.81 (95% CI 1.73–8.41) for patients < 90 mg/dl vs 
1.83 (95% CI 1.53–2.19) for patients > 90 mg/dl], and glucose < or > 100mg/dl 
(5.5mmol/l) [(p=0.004 for interaction, acOR 3.17 (95% CI 2.04–4.93) vs acOR 1.72 
(95% CI 1.42–2.08)], but not between subgroups above these levels of glucose. 
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Conclusions: Endovascular thrombectomy improved stroke outcomes compared to 
standard treatment regardless of glucose levels but the treatment effects were larger at 
lower glucose levels, with significant interaction effects persisting up to 90 to 100mg/dl 
(5.0-5.5mmol/l). Whether tight control of glucose improves the efficacy of endovascular 
thrombectomy following large vessel stroke warrants appropriate testing. 
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Introduction 
Glucose is essential for normal brain function but may also exacerbate ischemic brain 
injury through mechanisms occurring within the brain vasculature, microglia, neural 
cells, and infiltrating leukocytes.1 Observational studies have shown that hyperglycemia 
is associated with poor stroke outcomes,2 whether the patients are treated with 
intravenous thrombolysis or not. 3-5 Hyperglycemia has also been associated with less 
favorable outcomes in stroke patients treated with endovascular thrombectomy in 
observational studies, 6-8 and in one randomized controlled trial (RCT) that compared 
the Merci and the Solitaire FR device. 9 However, a post hoc analysis of the MR 
CLEAN trial found no evidence for effect modification of intra-arterial treatment by 
glucose > 140mg/dl (7.8mmol/l). 10 Hyperglycemia is frequent in the acute phase of 
ischemic stroke, 11 but its definition varies widely across stroke studies, with cutoffs 
ranging from 109.8mg/dl (6.1mmol/l) to >180mg/dl (9.9mmol/l) random glucose 
levels.12 Hyperglycemia promotes tissue acidosis and the production of reactive oxygen 
and nitrogen species (ROS) that increase infarct size, brain swelling, hemorrhagic 
transformation, blood–brain barrier disruption and results in more severe neurological 
deficits under experimental ischemic conditions. 13-14 Patients treated with endovascular 
thrombectomy have the highest rate of recanalization of the occluded vessel, and 
arguably have a greater exposure to redox mediated mechanisms which are activated by 
the re-oxygenation of the ischemic brain and also fueled by the levels of glucose.15 It is 
uncertain whether in patients with large vessel stroke treated with endovascular 
thrombectomy, glucose could be not only a negative prognostic factor, but also a 
treatment modifier of the efficacy of the procedure. Clarification of this important 
question is the main objective of the current analysis for it could provide evidence for or 
against strategies to maximize the benefits of endovascular thrombectomy by 
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optimization of glucose management in this population. To this end, we sought for 
modification of the effect of endovascular thrombectomy by glucose level in the 
randomized phase 3 trials in which stent retrievers were used for acute treatment of 
ischemic stroke. 
Methods 
The data that support the findings of this study are available from the corresponding 
author upon reasonable request. The highly effective reperfusion using multiple 
endovascular devices (HERMES) collaboration 15 pooled individual patient data from 
all randomized phase 3 trials in which stent retrievers or other second-generation 
devices were used in the majority of endovascular interventions for treatment of acute 
ischemic stroke, and for which a peer-reviewed, complete primary results manuscript 
was published by May 31, 2017. Comparative design features of the contributing trials 
have been described,15-16 and included MR CLEAN, 17 ESCAPE, 18 EXTEND-IA, 19 
SWIFT PRIME, 20 REVASCAT, 21 PISTE, 22 and THRACE23 trials. The HERMES 
executive committee (comprising representatives of each trial) confirmed that all 
eligible trials were included and contributed their trial data. All participants provided 
informed consent according to each trial protocol and each study was approved by the 
local ethics board. The current analysis was prospectively designed by one of the 
authors (AC), but not registered. We followed the PRISMA Guidelines (See 
supplementary material). 
In the HERMES trials, glucose was collected as part of the pre-randomization screening 
blood work and patients with whole blood or plasma glucose levels between 48mg/dl 
(2.7mmol/l) and 400mg/dl (22.2mmol/l) fulfilled the entry criteria of the pooled trials. 
The reported management of glucose in the early phase of AIS was not identical 
amongst the different studies, as two trials (ESCAPE and MR CLEAN) referred to 
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national standards and guidelines for glucose management, one trial (REVASCAT) 
recommended a target blood glucose level of less than 160mg/dl (8.9mmol/l) while 
advising against the correction of baseline glucose laboratory values to meet the 
inclusion criteria of the study, and four trials (EXTEND-IA, SWIFT PRIME, PISTE, 
THRACE) provided no specific recommendations for glucose management.  
The primary outcome was defined as the degree of disability at 3 months, assessed 
across 6 levels of the modified Rankin Scale (mRS), with ranks 5 and 6 combined into a 
single worst outcome rank (primary outcome). Secondary outcomes included (1) 
functional independence at 3 months, defined as mRS scores of 0 through 2; (2) 
excellent outcome at 3 months, defined as mRS score of 0 through 1; (3) early 
neurological recovery  at 24 hours, defined as a reduction in National Institutes of 
Health Stroke Scale (NIHSS) score from baseline of at least 8 points or reaching mRS 
of 0–1; and (4) complete reperfusion, defined as a modified treatment in cerebral 
infarction (mTICI) score 2b or 3 at the end of endovascular thrombectomy. Safety 
outcomes evaluated were 90-day mortality, and symptomatic intracranial hemorrhage 
(sICH) within 36 hours. sICH was classified according to the actual definitions used in 
each trial while ICH was defined as parenchymal hematoma type 2 (PH-2). 24 
Data were provided by the authors of all the trials meeting eligibility criteria and 
collected by independent statisticians. SB coordinated the creation of the unified 
database. We used a one-stage approach, defined as the use of individual patient data 
with analysis including covariates and random study effects to appropriately incorporate 
any between-study differences. 25 
To account for between-study variance in relationships among predictors and outcomes, 
the statistical models incorporated random effects for study and study-by-treatment 
interaction (in those models assessing both treatment groups). Analyses were based on 
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all randomized patients based on their original group of randomization, after excluding 
missing values for admission glucose and 90-mRS, and the relationship of glucose with 
clinical and radiological outcomes was evaluated principally through logistic regression 
models.  
A detailed description of the analytic approach is provided in the statistical analysis plan 
(Appendix).  The primary analysis evaluated whether glucose modified the effect of 
treatment on mRS at 90 days, when adjusted for pre-specified covariates using ordinal 
logistic regression adjusted for age, sex, NIHSS score at admission, prior use of IV 
alteplase, occlusion location (ICA/M1/M2), time from stroke onset to randomization, 
and history of diabetes. Treatment assignment was included as a variable with two 
levels: endovascular thrombectomy and standard care. Baseline and procedural 
characteristics were compared between treatment groups and between glucose 
subgroups using t-tests for continuous variables, Fisher’s exact test for binomial 
outcomes and Pearson’s chi-square for multinomial outcomes The interaction between 
glucose and treatment assignment on the primary outcome assessed glucose using 
subgroups defined by 10 mg/dl increments from 80 to 180mg/dl (4.9-9.9mmol/l); all 
subgroup results for the various cutoffs evaluated were then presented. Category-
specific effects were reported (in text and using figures) and the presence of significant 
interactions were noted. For this purpose, p-values are presented; adjustment for 
multiplicity of testing was applied in assessing the optimal cutoff for distinguishing 
treatment by glucose interaction. Secondary outcomes and safety outcomes were also 
adjusted for the same baseline prognostic factors. Statistical analyses were performed in 
SAS software version 9.4 (SAS Institute, Cary, NC, USA), and R version 3.3 (R 
Foundation for Statistical Computing, Vienna, Austria). All p-values presented are two-
sided, with values less than 0.05 defining statistical significance.   
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Results 
After pooling and screening data from all 7 trials in the HERMES collaboration, 
glucose was not available in 60 (3.4%) of 1764 patients, with 30 patients lacking 
glucose data in the endovascular group, and 30 patients lacking glucose data in the 
standard care group (Appendix Figure I).  
Across the entire study population, the median glucose on admission was 120mg/dl 
(6.6mmol/l) (IQR 104-140mg/dl) (5.7-7.7mmol/l), and the distribution of glucose levels 
in the whole study group was well balanced between the two treatment arms (Appendix 
Figure II). Results were consistent across the analysis methods and showed higher 
glucose levels to be significantly associated with worse outcomes including reduced 
excellent outcome (mRS 0-1), functional independence (mRS 0-2), and early 
neurological recovery, and increased all-cause mortality, and symptomatic hemorrhagic 
complications (Table 1). In contrast, blood glucose concentration was not associated 
with the occurrence of successful reperfusion at the end of endovascular thrombectomy.  
In the entire population, endovascular thrombectomy improved the primary outcome 
compared with standard care [acOR 2.00 (95% CI 1.69–2.38)]. Notwithstanding, the 
treatment effect on the primary outcome was found to be nonlinearly dependent on the 
levels of glucose (Figure 1), and significant treatment interactions were found for 
subgroup cutoffs of 90mg/dl (5.0mmol/l), 6% of the study sample, and 100mg/dl 
(5.5mmol/l), 17% of the study sample, but not for the subgroups of patients with 
glucose cutoffs above this level (Appendix Table I). After Bonferroni correction, for 
the primary outcome only the difference in treatment effect between glucose <100 
mg/dL and glucose ≥ 100 mg/dL remained significant.   For the glucose cutoff of 
90mg/dl (5.0mmol/l) (Figure 2A), there were significant interactions for the rates of 
functional independence (mRS 0 to 2), and mortality; for the glucose cutoff of 100mg/dl 
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(5.5mmol/l) (Figure 2B), there were significant interactions for functional 
independence, early neurological recovery, and mortality. The interaction effect 
between treatment assignment and glucose level was also highly significant when 
comparing patients with glucose <100mg/dL (5.5mmol/l) with those >100mg/dl 
(5.5mmol/l) (p=0.004) after Bonferroni adjustment for multiple comparisons against a 
threshold of 0.05/10 = 0.005; for the glucose cutoff of 110mg/dl (6.6mmol/l), there were 
significant interactions for functional independence (Appendix Table II). The 
magnitude of these associations were clinically meaningful: for every 100 patients with 
glucose <100mg/dl (5.5mmol/l) treated with endovascular thrombectomy, 45 will have 
a less disabled outcome than with best medical management, and 32 more will achieve 
functional independence (mRS 0–2) as a result of treatment; for every 100 patients with 
glucose >100mg/dl (5.5mmol/l) treated with endovascular thrombectomy, 23 will have 
a less disabled outcome than with best medical management, and 14 more will achieve 
functional independence (mRS 0–2) as a result of treatment 
The rates of excellent outcome and sICH showed no significant interactions with the 
treatment effect at any glucose cutoff.  
Patients with glucose levels <100mg/dl (5.5mmol/l) were younger, had a lower rate of 
diabetes, were more likely to have a history of tobacco use and had shorter time from 
stroke onset to randomization than patients without this range, but did not differ in 
baseline clinical stroke severity (according to NIHSS), occlusion location, affected 
hemisphere, or rates of hypertension, hyperlipidemia, and tPA use (Appendix Table 
III).  
The number needed to treat for benefit  to improve outcome by one mRS category at 3 
months was 2.2 in patients with glucose <100 mg/dl (5.5mmol/l) versus 4.4 in patients 
with glucose ≥100mg/dl (5.5mmol/l).  
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Discussion 
This meta-analysis of individual patient data from seven randomized trials provides post 
hoc evidence that endovascular thrombectomy improved the primary outcome (mRS at 
3 months) more effectively than standard care in patients with large vessel ischemic 
stroke regardless of glucose levels at stroke onset. The analysis also identified that the 
patients with glucose ranging between 90 and 100mg/dl (5.0-5.5mmol/l) at stroke onset 
(17% of the study sample) had the largest treatment effect in favor of the intervention. 
Consistently, in subgroups with lower glucose levels the larger benefits also extended to 
predefined secondary outcomes including functional independence (dichotomized mRS 
0-2), early neurological recovery at 24 hours, and all-cause mortality, while there were 
no significant differences in the rate of symptomatic or asymptomatic hemorrhagic 
complications.  
The differences in efficacy between the randomly assigned treatments were significantly 
lower at glucose levels above 100mg/dl (5.5mmol/l).The study included a large cohort 
of diabetic and non-diabetic patients and the findings were consistent with those of prior 
studies that did not include patients treated with endovascular thrombectomy1, 9, 26-27 
showing that higher glucose levels were associated with worse functional outcomes at 3 
months, and were also associated with increased all-cause mortality, and greater risks of 
symptomatic hemorrhagic complications. Hyperglycemia was deemed to impair the 
efficacy of intravenous thrombolysis in previous studies, 5 while we found similar rates 
of successful reperfusion following endovascular thrombectomy regardless of glucose 
levels, arguing that the worse outcomes found in patients with higher glucose levels 
were not the consequence of impaired brain reperfusion following the endovascular 
procedure.    
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The key question is whether lower glucose is a simply a marker for patients who have a 
better prognosis, or if acutely lowering glucose could improve prognosis.  The benefits 
of lowering glucose concentration in patients with acute ischemic stroke remain to be 
demonstrated, but all the reported previous attempts have been unsuccessful.28-29 In the 
GIST‐UK trial, 24-hour glucose potassium insulin (GKI) infusion targeted to maintain 
glucose at 72-126mg/dl (4–7mmol/l) did not improve outcome in patients with 
admission glucose concentration between 108-306mg/dl (5.9–16.9mmol/l). 28 However, 
this study was compromised by under‐recruitment, late treatment initiation, and 
marginal reduction of blood glucose [10mg/dl (0.5mmol/l)] compared with control. 28 In 
the SELESTIAL trial, 29 GKI infusion targeted to maintain blood glucose between 72–
126mg/dl (4 –7mmol/l), did lower blood glucose from 6 to 12 hours after GKI initiation 
and attenuated an increase in brain lactate, but the therapy did not affect cerebral infarct 
growth, and hypoglycemia [<72mg/dl (4.0mmol/l)] occurred in 76% of GKI-treated 
subjects although it was predominantly asymptomatic. 29 The mean glucose levels 
obtained in these trials ranged between 105-112mg/dl (5.8-6.2mmol/l), and there was a 
very low risk of symptomatic hypoglycemia. The SHINE trial (#NCT01369069) is 
currently determining the safety and efficacy of attaining a glucose range of 80–
179mg/dl (4.4‐9.9mmol/l) versus 80–130mg/dl (4.4‐7.2mmol/l) for up to 72 h, starting 
within 12 h of stroke symptom onset, and the TEXAIS trial (NCT03287076), is 
comparing exenatide to standard of care in patients with acute ischemic stroke 
commencing treatment within 9 hours of symptom onset, although in this trial there is 
not a target glucose level. However, in none of the ongoing trials it is anticipated the 
inclusion of a sufficient number of patients that will receive endovascular 
thrombectomy to detect a treatment effect in that subgroup. Altogether, it appears that 
moderate lowering of glucose levels in patients with acute ischemic stroke not treated 
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with endovascular thrombectomy prevents lactic acidosis, but this effect seems not to 
translate into clinical benefits. Indeed, extracellular lactate accumulation is not a crucial 
determinant of brain injury in experimental hyperglycemia, 30for prevention of tissue 
acidosis does not avoid brain tissue damage under hyperglycemic conditions.31 
Endovascular thrombectomy achieves a high rate of successful reperfusion, facilitating 
the reentry of oxygen into the ischemic brain to a much larger extent than any other 
therapeutic options. Because oxygen boosts the formation of free radicals in parallel 
with the availability of glucose, 2-3 it is possible that patients receiving endovascular 
thrombectomy are more vulnerable to the redox mediated effects of glucose. Classical 
experimental studies of focal cerebral ischemia support the significance of reperfusion 
in contributing to the detrimental effect of hyperglycemia.32  
The results of this post hoc pooled-data meta-analysis need to be interpreted with 
caution and cannot be used to change clinical recommendations. These data do provide 
clinical justification for the study of tight glucose management in patients receiving 
endovascular thrombectomy. Testing a glucose target of 90-100mg/dl (5.0-5.5mmol/l) 
seems justified, despite the risk that this approach might increase the occurrence of 
hypoglycemia, which has been predominantly asymptomatic in previous trials.28-29 
Therapeutic alternatives without the risk of hypoglycemia could also be considered for 
further clinical testing, including the administration of the antioxidant uric acid. In the 
URICOICTUS trial, 33 in addition to the antioxidant uric acid or placebo, all the patients 
received intravenous thrombolysis within 4.5 hours of stroke onset, and some also 
received rescue endovascular thrombectomy. 34 In this trial, uric acid therapy reduced 
infarct growth and improved the functional outcome at 3 months more effectively than 
placebo even in hyperglycemic patients, 35supporting the idea that the toxicity of 
hyperglycemia can be minimized by enhancing antioxidant exposure. Indeed, 
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inactivation of the glucose-dependent nicotinamide adenine dinucleotide phosphate 
oxidase enzyme blocks neuronal ROS production and negates the deleterious effects of 
hyperglycemia. 36 
Some limitations of this pooled data analysis include the lack of information on the 
longitudinal course of glucose at follow up, the undocumented use of lowering glucose 
drugs, or whether glucose concentration was measured in venous or capillary samples. 
Three of the trials analyzed patients that were treated following widely accepted 
guidelines recommending the administration of insulin in patients with glucose 
concentrations >140mg/dl (7.8mmol/l) to 185mg/dl (10.3mmol/l), although four trials 
provided no specific treatment recommendations. Low glucose at stroke onset could be 
associated with good prognostic variables not measured in this study, such as lower 
body mass index, better collaterals, or less need for general anesthesia. Given the 
exploratory analyses testing the effect modification of pretreatment glucose, concerns 
about type 1 error with multiple testing might arise, but the p-value for interaction with 
glucose 100 mg/dl cut-off values remained significant after Bonferroni correction. 
Further, the pooled patients were treated at many centers in multiple countries on 4 
continents, suggesting wide applicability.   
In conclusion, in this individual patient data meta-analysis of 7 randomized clinical 
trials of patients with large-vessel ischemic stroke, the effect of endovascular 
thrombectomy on functional outcome at 3 months compared to standard treatment was 
severely diminished with increasing glucose levels.  
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Figure legends 
 
Figure 1: Modification of pretreatment glucose on treatment effect of endovascular 
thrombectomy over standard care on the rate of functional independence (modified 
Rankin Scale 0 to 2).  
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Figure 2: Forest plots of odds ratios for the model of main treatment effects of 
endovascular thrombectomy or standard care according to admission glucose 
concentration < or > 90mg/dl (5.0mmol/l) (Fig 2A) and 100mg/dl (5.5mmol/l) (Fig 2B) 
in the HERMES population.  
ENR=early neurological recovery; mRS=modified Rankin Scale; sICH=symptomatic 
intracerebral hemorrhage. 
 
 
Table 1: Associations between continuous glucose levels and outcomes 
 n  Glucose, mg/dl  
Mean+SD  
[Median] (IQR)  
P  
value  
Unadjusted OR (95% 
CI) 
a 
 
P  
value  
Adjusted OR (95% 
CI) 
b
  
P  
value  
Excellent 
outcome  
  mRS 0-1 
  mrS 2-6 
 
 
383 
1304 
120.2 +/-  33.5  
[113.4] (100·0,130.0)  
134.8 +/-  74.6  
[121.8] (106.2,145.0) 
<0.001  
0.92 (0.88, 0.95) <0.0001  0.93 (0.89, 0.96) <0.0001  
Good outcome 
  mRS 0-2 
  mrS 3-6 
 
 
662 
1025 
123.7 +/-  54.8  
[114.5] (101.8,133.2) 
136.5 +/-  74.6  
[123.0] (107·3,147.0) 
<0.001  
0.92 (0.90, 0.95) <0.0001  0.93 (0.90, 0.96) <0.0001  
Death  
  Yes 
  No 
 
271 
1425 
147.1 +/- 111.3  
[129.1] (107.3,157.0) 
128.4 +/-  55.1  
[118.2] (104.4,138.2) 
<0.0001  
1.07 (1.04, 1.10) <0.0001  1.06 (1.03, 1.09) <0.0001  
ENR  
  Yes 
  No 
 
602 
1046 
123.1 +/-  34.6  
[115.2] (102.6,134.0) 
134.5 +/-  63.6  
[121.8] (106.0,145.5) 
<0.0001  
0.92 (0.88, 0.96) <0.001  0.93 (0.89, 0.97) 0.002  
sICH 
  Yes 
  No 
 
62 
1612 
172.9 +/- 213.4  
[127.5] (110.9,161.0) 
129.6 +/-  54.3  
[119.0] (104.4,140.0) 
<0.0001  
1.07 (1.03, 1.12) 0.001  1.06 (1.02, 1.11) 0.006  
mTICI score 
  2b/3 
  0-2ª 
 
 
535 
179 
129.5 +/-  55.5  
[119.0] (105.0,140.0) 
140.1 +/- 127.2 [121.8] 
(107.3,143.0) 
0.124  
0.97 (0.93, 1.01) 0.175  0.97 (0.93, 1.02) 0.242  
CI=confidence interval; ENR=early neurological recovery; sICH=symptomatic intracerebral hemorrhage; mRS=modified Rankin Scale; OR, odds ratio; 
mTICI=modified Thrombolysis In Cerebral Infarction.  
a
Odds ratio for experiencing the first listed outcome; the incremental unit of glucose is 10 mg/dL  
b
 Adjusted for age, gender, NIHSS, occlusion location, tPA administration , history of diabetes, and time from onset to randomization  
 
